期刊文献+

2型糖尿病患者血清hs-CRP、FIB检测的临床价值 被引量:2

Clinical Value of Detection of Serum hs-CRP,FIB in Type 2 Diabetes Mellitus Patients
下载PDF
导出
摘要 目的研究超敏C-反应蛋白(hs-CRP)和纤维蛋白原(FIB)预测2型糖尿病并发动脉粥样硬化的临床价值。方法对50例2型糖尿病患者和30例健康体检者同时检测hs-CRP、FIB。采用乳胶增强透射比浊法测定hs-CRP,用Clauss方法检测FIB。结果2型糖尿病患者的hs-CRP、FIB均明显升高,与正常对照组比较有显著性差异(P<0.01)。结论hs-CRP、FIB作为急性时相反应蛋白,在预测和监视2型糖尿病并发动脉粥样硬化方面有重要的临床价值,联合测定为2型糖尿病患者并发症的早期预防、诊断、治疗及预后评价手段提供了理论依据。 Objective Discovering clinical value of ultra high-sensitivity C-response protein(hs-CRP)and fibrinogen(FIB)to forecast type 2 diabetes mellitus(T2DM)concurrent atherosclerosis.Methods Detecting hs-CRP and FIB in fifty T2DM patients and thirty healthy people simultaneously by using the emulsion enhancement transmission turbidimetric method and the Clauss method.Results Both hs-CRP and FIB level are obviously elevated in T2DM patients with atherosclerosis comparing to normal controls.There is a significant difference between two groups(P〈0.01).Conclusion hs-CRP and FIB are fast response proteins and are valuable to forecasting and monitoring T2DM with atherosclerosis;The conciudion also provide the theory basis for early prevention,diagnosis,treatment and prognosis in T2DM with complication.
出处 《中国现代医生》 2007年第05S期13-13,19,共2页 China Modern Doctor
关键词 2型糖尿病 超敏C-反应蛋白 纤维蛋白原 动脉粥样硬化 血清 临床价值 Type 2 diabetes mellitus High-sensitivity C-response protein Fibrinogen Atherosclerosis.
  • 相关文献

同被引文献16

  • 1黄斌,罗琳,韩文群,谢雪,罗先策,魏东.马来酸罗格列酮对2型糖尿病患者糖脂代谢、胰岛素抵抗及血清炎症因子的影响[J].中国糖尿病杂志,2006,14(1):9-10. 被引量:27
  • 2孙亮,张新卿.脑血管病及血管性危险因素与血管性认知功能损害[J].中国实用内科杂志,2007,27(13):1054-1056. 被引量:15
  • 3Ford ES. Body mass index, diabetes, and C - reactive protein among U. S. adults. Diabetes Care, 1999,22(12) : 1971 - 1977.
  • 4Pickup JC, Crook MA. Is type 2 diabetes mellitus a disease of the innate immune system? Diabetologia, 1998, 41 ( 10 ) : 1241 - 1248.
  • 5Pradhan AD, Manson JE, Nader Rifai N, et al. C reactive reactive protein, interleukin - 6, and risk of developing type 2 diabetes mellitus. JAMA, 2001,286 (3) : 327 - 334.
  • 6Taniguchi A, Nagasaka S, Fukushima M, et al. C - reactive protein and insulin resistance in non - obese Japanese type 2 diabetic patients. Metabolism, 2002,51(12) : 1578 - 1581.
  • 7Pradhan AD, Manson JE, Rifai N, et al. C - reactive protein, interleukin 6,and risk of developing type 2 diabetes mellitus. JAMA, 2001,286(3) :327 - 334.
  • 8Spiegelrnan BM. PPAR-gamma: adipogenic regulator and thiazolidinedrone receptor. Diabetes, 1998,47(4) :507 - 514.
  • 9Balfour JA, Plosker GL. Rosiglitazone. Drugs, 1999, 57 (6). 921.
  • 10Eposito K, Ciotola M, Carlo D, et al. Effecf of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome. Diabetes Care, 2006,29 ( 5 ) : 1071 - 1076.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部